There must be measurable disease at study entry\r\n* Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)Xx_NEWLINE_xXMust not have received any prior radiation to any sites of measurable diseaseXx_NEWLINE_xXMeasurable or non-measurable (evaluable) tumor parameter(s); non-measurable tumor parameters will be defined as not having bi-dimensional measurements (i.e., gastric or marrow involvement) but can be followed for response by other diagnostic tests such as gallium, PET imaging and/or bone marrow biopsyXx_NEWLINE_xXParts A & C: patients must have either measurable or evaluable diseaseXx_NEWLINE_xXParts B, D & E: patients must have measurable disease for Parts B1-B6, D1-D5, E3 and E4; melanoma patients in Part B7 must have either measurable or evaluable disease; neuroblastoma patients in Parts B8 and D6 must be evaluable for MIBG response without evidence of RECIST measurable lesionsXx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXImaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 21 days prior to randomization. Patients with either measurable disease or non-measurable evaluable disease are eligible.Xx_NEWLINE_xXSubjects must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteriaXx_NEWLINE_xXDisease status:\r\n* Part A: Patients must have either measurable or evaluable disease\r\n* Parts B and C: Patients must have measurable disease on imagingXx_NEWLINE_xXPart A: Patients must have either measurable or evaluable diseaseXx_NEWLINE_xXPart D: Patients must have measurable disease for Part DXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXMust have at least 1 lesion with measurable diseaseXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXRadiologically measurable or clinically evaluable diseaseXx_NEWLINE_xXPatients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to sub-study registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to sub-study registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registrationXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXRe-registration: measurable diseaseXx_NEWLINE_xXPatients must have measurable disease; all sites of disease must be evaluated within 4 weeks prior to randomizationXx_NEWLINE_xXPatients must have measurable disease per RECIST 1.1; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within 28 days prior to registration; if the only measurable disease is cutaneous or subcutaneous, lesions must be at least 10 mm in greatest dimension and able to be serially recorded using calipers and photographs; tests used to assess non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment FormXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have progressive disease while receiving androgen deprivation therapy defined by any one of the following as per the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria for PSA, measurable disease or non-measurable (bone) disease during treatment with ADT:\r\n* PSA: At least two consecutive rises in serum PSA, obtained at a minimum of 1-week intervals, with the final value >= 2.0 ng/mL\r\n* Measurable disease (by RECIST 1.1): > 20% increase in the sum of the longest diameters of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be more that 15 mm to be assessed for change in size\r\n* Non-measurable (bone) disease: The appearance of two or more new areas of uptake on bone scan (or NaF PET/CT) consistent with metastatic disease compared to previous imaging during castration therapy; the increased uptake of pre-existing lesions on bone scan will not be taken to constitute progression, and ambiguous results must be confirmed by other imaging modalities (e.g. X-ray, CT or MRI)Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have measurable disease; baseline measurements and ALL sites of disease must be obtained within 4 weeks to registrationXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXCOHORT A: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is deemed resectable; the decision to perform surgery on patients must be based on good clinical judgment; eligible patients for surgical resection must have disease that, in the judgment of the surgeon, is deemed completely resectable resulting in free surgical margins; patients must have residual disease after initial biopsy which can be measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; residual disease can either be confirmed with fine-needle aspiration (FNA) or if measurable disease is present, no FNA needs to be obtained ORXx_NEWLINE_xXPatients must have measurable disease documented by CT or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 1 registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to step 1 registration; all disease must be assessed and documented on the RECIST 1.1 and modified RECIST baseline tumor assessment formXx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: \r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation\r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease and/or non-measurable disease\r\n* Measurable disease, defined as bidimensionally measurable lesions with clearly defined margins by magnetic resonance imaging (MRI) scans, with a minimum diameter of 10 mm in both dimensions\r\n* Progressive disease required in cohort B, defined as any progressive measurable disease after surgery and radiation; progressive or recurrent disease is not required in cohort A, but is allowed provided it is a new diagnosis and patient has not received prior treatmentXx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG)+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease: \r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation \r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n** Bone lesions without an associated soft tissue mass >= 10 mm in greatest diameter; bone lesions with an associated soft tissue mass >= 10 mm in greatest diameter imaged by computed tomography (CT) or MRI are considered measurableXx_NEWLINE_xXMeasurable disease based on Cheson 2007 criteriaXx_NEWLINE_xXPhase 2: Measurable disease meeting the following criteria:Xx_NEWLINE_xXFor patients with solid tumors, one of the following must apply: a. Patient has measurable disease as defined by the immune-related response criteria (irRC), b. Patient has ovarian cancer and has disease evaluable by CA-125 onlyXx_NEWLINE_xXSubjects must have measurable or evaluable disease:\r\n* Evaluable disease must be evidenced by computed tomography (CT) or positron emission tomography (PET) scans (abnormal PET scans may be used as long as the CT portion is of diagnostic quality)\r\n* Subject must have at least one objective measurable disease parameter:\r\n** Measurable disease on cross sectional imaging that is >= 2 cm in the longest diameter and measurable in 2 perpendicular dimensions\r\n** Splenomegaly > 13 cm in cranio-caudal dimension as measured by CTXx_NEWLINE_xXFor patients enrolled in the Dose Escalation Phase, one or more tumors measurable on radiograph or CT scan, or evaluable disease defined as non-measurable lesions per RECIST v. 1.1 (e.g., malignant ascites). All patients enrolled to the Randomized Study Phase must have measurable disease only.Xx_NEWLINE_xXPatients may have measurable disease only, non-measurable disease only, or both (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1); concomitant treatment with bone-targeted therapies such as RANKL inhibitors or bisphosphonates is allowed; it is anticipated that most patients will have measurable disease, given the behavior of HER2+ metastatic breast cancerXx_NEWLINE_xXRelapsed patients must have measurable disease; patients without measurable disease may be considered after discussion with principal investigatorXx_NEWLINE_xXDocumented metastatic disease (may be measurable or non-measurable)Xx_NEWLINE_xXSubjects must have measurable disease.Xx_NEWLINE_xXAt least 1 measurable lesion for solid tumorXx_NEWLINE_xXMeasurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease lesion > 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CTXx_NEWLINE_xXPresence of measurable disease based on RECIST 1.1; subjects with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accuratelyXx_NEWLINE_xXMeasurable disease confirmed by central lab at Screening, defined by at least 1 of the following:Xx_NEWLINE_xXMeasurable disease, defined as any quantifiable monoclonal protein valueXx_NEWLINE_xXMust have measurable MMXx_NEWLINE_xXProgressive OR residual disease, as defined by the following:\r\n* Progressive disease, as defined as an increase in size of the measurable primary lesion on imaging by greater than 25% (bidirectional area); the change must occur between scans separated by no more than 24 months\r\n* Residual measurable disease: for grade II or III meningioma, residual measurable disease immediately after surgery without requirement for progression; residual measurable disease will be defined by measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in one dimension\r\n* Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease in the radiated field after completion of radiation; >= 24 weeks must have elapsed from completion of radiation to registration; patients that have progressive disease outside of the radiation field do not need to wait 24 weeks from completion of radiationXx_NEWLINE_xXMeasurable disease: measurable disease is defined by a main lesion measurable on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins and >= 10 mm in one dimension; multifocal disease is allowed as long as one lesion meets criteria for measurable disease and progressive diseaseXx_NEWLINE_xXMeasurable disease defined by laboratory test resultsXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease defined as any of the following:Xx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPART I: participants are required to have only evaluable disease (disease that is visible on imaging studies but does not meet RECIST criteria for measurable disease)Xx_NEWLINE_xXPatients must have measurable disease and be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelinesXx_NEWLINE_xXPatients must have active, measurable disease to be included in the studyXx_NEWLINE_xXMeasurable disease by RECISTv1.1 criteriaXx_NEWLINE_xXCOHORT A: Measurable CNS disease (one intracranial lesion >= 5 mm)Xx_NEWLINE_xXCOHORT B: Measurable CNS disease (one intracranial lesion >= 5 mm)Xx_NEWLINE_xXCOHORT D: Measurable CNS disease (one intracranial lesion >= 5 mm) from any solid tumorXx_NEWLINE_xXMeasurable disease in the brain, defined as at least 1 lesion measuring >= 5 mm on imaging at the time of registrationXx_NEWLINE_xXMeasurable Disease Progression: >20% increase in the sum of diameters of measurable lesions from the time of maximal regression or appearance of one or more new lesions.Xx_NEWLINE_xXGroup A subjects must have measurable or evaluable disease per the appropriate disease criteria.Xx_NEWLINE_xXRadiologically measurable diseaseXx_NEWLINE_xXPatient must have measurable or evaluable diseaseXx_NEWLINE_xXSubjects with measurable disease.Xx_NEWLINE_xXRadiologically measurable and clinically evaluable diseaseXx_NEWLINE_xXAt least one bi-dimensionally measurable lesionXx_NEWLINE_xXSubjects must have radiographically measurable disease at the time of study enrollment to be eligible; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG)+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one sliceXx_NEWLINE_xXPatients may have either non-measurable disease OR measurable diseaseXx_NEWLINE_xXPatients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollmentXx_NEWLINE_xXPatients must have measurable disease (defined as >= 1.5 cm in diameter)Xx_NEWLINE_xXMeasurable disease, defined by the 2014 Lugano Classification CriteriaXx_NEWLINE_xXAt least one measurable lesion.Xx_NEWLINE_xXMeasurable disease or non-measurable disease; for patients with non-measureable disease, they must also have a cancer antigen (CA)-125 measurement of > 35 U/mL or 2 X their documented nadir on 2 separate measurements 1 week apartXx_NEWLINE_xXMeasurable or evaluable disease.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease; patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation\r\n* Measurable disease: patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with the longest diameter >= 10 mm by local radiology review (measurable non-CNS disease is not required for study participation)\r\n* Patients will be defined as HER2 positive (+) if either the primary tumor and/or the metastasis are HER2-positive, defined as 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) >= 2.0Xx_NEWLINE_xXHave measurable diseaseXx_NEWLINE_xXSubjects must have measurable disease of at least 1.5 cm in diameterXx_NEWLINE_xXPatients must have measurable residual disease, defined as tumor that is measurable in two diameters on magnetic resonance imaging (MRI); diffuse leptomeningeal disease is not considered measurableXx_NEWLINE_xXMeasurable disease, defined by the Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXPatients must have bi-dimensionally measurable disease (at least 1 cm); NOTE: patients with fully resected disease are eligible, and will be evaluable for all toxicity and efficacy endpoints except objective responseXx_NEWLINE_xXPatients must have measurable or non-measurable (evaluable) disease recurrence\r\n* Recurrence must be documented based on a combination of clinical and imaging parameters, consistent with routine clinical practice, with or without histologic confirmation\r\n* Patients may have had any number of relapses and be eligible for the studyXx_NEWLINE_xXAll patients must have measurable disease documented by CT, MRI, or nonmeasurable disease documented by physical exam within 28 days prior to registrationXx_NEWLINE_xXPatients must have at least one measurable site of diseaseXx_NEWLINE_xXEvaluable diseaseXx_NEWLINE_xXMeasurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)Xx_NEWLINE_xXNo measurable target lesions.Xx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXParticipants enrolling to the phase I portion of the trial must have evaluable or measurable diseaseXx_NEWLINE_xXMeasurable, secretory disease as defined by any of the following:Xx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXEvaluable disease; either measurable on imaging or with informative tumor marker.Xx_NEWLINE_xXMeasurable disease by breast ultrasound and MRIXx_NEWLINE_xXMeasurable disease per the Lugano criteriaXx_NEWLINE_xXParticipants must have evaluable or measurable diseaseXx_NEWLINE_xXPart 2 only: Presence of radiographically measurable disease (defined as the presence of ?1 lesion that measures ?10 mm [?15 mm for lymph nodes]). Measurable disease that was previously radiated is only permitted if progressing.Xx_NEWLINE_xXPhase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).Xx_NEWLINE_xXMust have evaluable or measurable disease; subjects with lymphoma must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma must be present; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapyXx_NEWLINE_xXPatients must have measurable disease by the Lugano criteriaXx_NEWLINE_xXDuring dose escalation only, participants not meeting the above criteria for measurable disease should, at least, have measurable bone marrow plasmacytosis (greater than or equal to [>=] 10 percent [%]) and/or plasmacytoma (>=1 centimeter [cm] in diameter) detected by physical examination or imaging.Xx_NEWLINE_xXFor B-cell NHL subjects, measurable disease by imaging scan.Xx_NEWLINE_xXParticipants enrolling to the phase I portion of the trial must have evaluable or measurable diseaseXx_NEWLINE_xXParticipants must have at least one RECIST v1.1 measurable non-central nervous system (CNS) based lesions; palliative radiation must be indicated for at least one measurable or non-measurable lesions (including bone lesion), and this lesion must be a candidate for radiation to a dose of 30 Gy of radiation over 5 fractions as deemed by a treating radiation oncologist; one measurable lesion must be in a location where it will not be incorporated into the radiation fields so systemic response can be assessed; however, inclusion of patients with more than 10 measurable lesions is strongly discouraged and all patients must have life expectancy > 6 monthsXx_NEWLINE_xXParticipants must have measurable disease in at least one dimension of at least 10 mm in diameter or thickness, according to modified RECIST for pleural malignant mesothelioma; bone metastases are not considered measurable; prior radiation to the only site of measurable disease will make the participant ineligible unless the lesion has been demonstrated to grow after completion of radiation therapyXx_NEWLINE_xXDocumented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollmentXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXDisease must be measurable according to the corresponding guidelinesXx_NEWLINE_xXHas ?1 injectable lesion which is measurable and amenable to injection and biopsy.Xx_NEWLINE_xXMeasurable disease by CT or MRIXx_NEWLINE_xXPatients with neuroblastoma who do not have measurable disease but have iodine-131 - meta-iodobenzylguanidine positive (MIBG+) evaluable disease are eligible.Xx_NEWLINE_xXPart A: Patients must have either measurable or evaluable diseaseXx_NEWLINE_xXPart B: Patients must have measurable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients who do not have measurable disease on MRIXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXRadiologically-measurable diseaseXx_NEWLINE_xXMeasurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable; any tumor mass > 1.5 cm is acceptable; lesions that are considered non-measurable include the following:\r\n* Bone lesions (lesions if present should be noted)\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Lymphangitis cutis/pulmonis\r\n* Bone marrow (involvement by lymphoma should be noted)Xx_NEWLINE_xXPresence of measurable disease.Xx_NEWLINE_xXSubjects must have measurable disease defined as at least 1 of the following:Xx_NEWLINE_xXAt least 1 measurable lesion on imaging. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapyXx_NEWLINE_xXPatients must have measurable or evaluable disease that is FDG avid with standardized uptake value (SUV) > 3 on PET/CTXx_NEWLINE_xXMeasurable or evaluable disease.Xx_NEWLINE_xXApproximately 60 out of 80 patients with mCRPC enrolled must have measurable disease (approximately 30 out of 40 in each of the mCRPC Cohorts) that is suitable for repeated measurements. Enrollment will be monitored to ensure the required number of patients with measurable disease enter the study.Xx_NEWLINE_xXMeasurable disease before start of pre-study nivolumab treatmentXx_NEWLINE_xXmeasurable disease based on central protein assessmentXx_NEWLINE_xXAt least one bidimensionally measurable lesionXx_NEWLINE_xXMeasurable metastatic disease.Xx_NEWLINE_xXRadiologically or visually measurable recurrent or metastatic disease that is measurable and at least 10mm in longest dimension.Xx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXAt least one measurable lesion at baselineXx_NEWLINE_xXPatients who have measurable disease after diagnostic biopsyXx_NEWLINE_xXMeasurable disease by tumor imaging with at least one lesion >= 1.5 cm in at least one dimensionXx_NEWLINE_xXPatients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysisXx_NEWLINE_xXPatients must have at least 1 measurable metastatic lesion by RECIST1.1 criteriaXx_NEWLINE_xXPatient with a TP53wt locally advanced or metastatic solid malignancy and with measurable or non-measurable (but evaluable) disease as determined by RECIST 1.1 criteria.Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have radiographically measurable diseaseXx_NEWLINE_xXMeasurable disease (according to RANO guidelines)Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPatients must have evaluable or measurable diseaseXx_NEWLINE_xXMeasurable disease of at least 1.5 cm as documented by radiographic techniqueXx_NEWLINE_xXPatients in expansion cohorts A and B must have measurable diseaseXx_NEWLINE_xXPatients may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by Response Evaluation Criteria in Solid Tumors [RECIST] but visible on computed tomography [CT] scan); patients with third space fluid (for example pleural effusions) as only site of disease will not be eligibleXx_NEWLINE_xXParticipants must have measurable disease, defined as lymphocytosis >= 5,000/ul, or at least one palpable or CT measurable lesion > approximately 1.5 cm, or bone marrow involvement > approximately 30%Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPhase 1: patients may have measurable or non-measurable disease; measurable disease via RECIST 1.1 is required for Phase 2 patientsXx_NEWLINE_xXPatients must have measurable disease defined by at least 1 of the following 3 measurements:Xx_NEWLINE_xXHave evaluable disease; lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXMeasurable disease defined as any of the following:Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHas measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesionXx_NEWLINE_xXRadiographically measurable disease by RECIST version 1.1 in at least one site not previously treated with chemoembolization, radioembolization, radiation, or other local/liver-directed procedures (i.e. must have at least one measurable target lesion, either within the liver or in a measurable metastatic site); a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptableXx_NEWLINE_xXSTRATUM A: Evaluable disease, as defined as meeting any of the following:\r\n* Patients who have measurable disease \r\n* Patients with radiologically discernible but non-measurable lesions (i.e. leptomeningeal disease)\r\n* Patients with cerebrospinal fluid (CSF) positive diseaseXx_NEWLINE_xXSTRATUM B: Evaluable disease, as defined as meeting any of the following:\r\n* Patients who have measurable disease \r\n* Patients with radiologically discernible but non-measurable lesions (i.e. leptomeningeal disease)\r\n* Patients with CSF positive diseaseXx_NEWLINE_xXSTRATUM C: Evaluable disease, as defined as meeting any of the following:\r\n* Patients who have measurable disease \r\n* Patients with radiologically discernible but non-measurable lesions (i.e. leptomeningeal disease)\r\n* Patients with CSF positive diseaseXx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXPatients must have measurable disease.Xx_NEWLINE_xXNHL only- at least one measurable lesionXx_NEWLINE_xXHas measurable disease per investigator assessmentXx_NEWLINE_xXMeasurable disease, with the exception of prostate cancerXx_NEWLINE_xXHave measurable disease (1.5 cm or greater in the longest diameter of nodal or extranodal disease)Xx_NEWLINE_xXPatients must have measurable disease by RECIST v1.1, or evaluable disease with bone metastases demonstrated by Tc99 bone scan; patients with bone metastases only are allowed (NOTE: nodes >= 1.5 cm (not >= 2 cm) in the short axis are considered measurable, per The Prostate Cancer Working Group 3 [PCWG3])Xx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease:\r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n** Previously radiated lesions that have not demonstrated clear progression post radiation\r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMust have at least 1 lesion with measurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable disease for the dose escalation portion of the study and measurable disease for the expanded cohort portion of the study (except for patients in the CNS metastases and leptomeningeal cohorts).Xx_NEWLINE_xXPatients must have radiographically measurable diseaseXx_NEWLINE_xXPatients must have bi-dimensionally measurable disease defined as at least one lesion that can be accurately measured in at least two planes in order to be eligible for this studyXx_NEWLINE_xXMeasurable Disease\r\n* Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)\r\n* Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lungXx_NEWLINE_xXPatients must have evaluable OR measurable diseaseXx_NEWLINE_xXMeasurable disease (at least one target lesion)Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease by RANO criteriaXx_NEWLINE_xXSubjects must have evaluable disease for the dose escalation, and measurable disease for the dose expansion.Xx_NEWLINE_xXPatients must have measurable disease per irRECIST criteria for part 2 (dose expansion)Xx_NEWLINE_xXHave measurable disease based on iwCLL or Lugano criteriaXx_NEWLINE_xXPatients with a measurable disease, defined by a node or mass with the longest diameter >= 1.5 cm.Xx_NEWLINE_xXPatients with PTCL should have radiographically measurable disease >= 1.5 cm.Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease that can be accurately measured in at least one dimension as ? 2.0 cm with CT, ultrasound, or MRI techniques; extranodal disease that is measurable by FDG-PET imaging only will also be allowed; Note that if an excisional biopsy was performed that removed the sole site of measurable disease, the patient will not be eligible for leukapheresis and generation of CAR T cell product; measurable disease can be based on the imaging study done during the screening unless the patient received treatment in the interim, in which case imaging should be repeatedXx_NEWLINE_xXMeasurable disease at Screening as defined by any of the following:Xx_NEWLINE_xXMeasurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable nodal disease measuring at least 1.5 cm in longest dimension, or splenomegalyXx_NEWLINE_xXPatients must have measurable or non-measurable disease that is evaluable per RECIST 1.1;Xx_NEWLINE_xXSubjects must have measurable or evaluable diseaseXx_NEWLINE_xXSubject has measurable disease defined as a tumor that is measurable in 2 perpendicular diameters on MRI. For a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (ie, visible on 2 or more axial slices)Xx_NEWLINE_xXMust be determined to have metastatic or unresectable disease, as determined by treating physician; (must have at least evaluable disease, but does not need to be measurable disease by RECIST 1.1)Xx_NEWLINE_xXMust have evaluable or measurable disease; subjects with lymphoma must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapyXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXDOSE ESCALATION COHORT: Measurable disease is not required for enrollmentXx_NEWLINE_xXDocumented disease that is radiographically measurableXx_NEWLINE_xXHave measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)Xx_NEWLINE_xXHave measurable disease based on irRECISTXx_NEWLINE_xXat least 1 measurable lesion on imaging.Xx_NEWLINE_xXMeasurable disease by irRECISTXx_NEWLINE_xXMeasurable disease as defined by modified PCWG3 using iRECIST criteriaXx_NEWLINE_xXMeasurable disease according to the Lugano classificationXx_NEWLINE_xXMust have measurable disease defined by:Xx_NEWLINE_xXSurgery, radiotherapy, or lesion ablative procedure to the only area of measurable/evaluable diseaseXx_NEWLINE_xXFor dose escalation phase, patients may have evaluable or measurable disease. For ovarian cancer, if no measurable disease is present, patients should have assessable disease such as pleural effusion, ascites, with CA-125 Gynecological Cancer Intergroup (GCIG) criteriaXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMust have measurable disease defined by at least 1 of the following 3 measurements:Xx_NEWLINE_xXPatients must have at least one focus of measurable metastatic diseaseXx_NEWLINE_xXRadiographically measurable disease per mRECIST 1.1Xx_NEWLINE_xXOne previously unirradiated lesion amenable to radiotherapy 8 Gy x 3 and can meet dose constraints, and another unirradiated measurable lesion >= 1 cm in size outside the radiation field that can be used as measurable diseaseXx_NEWLINE_xXMeasurable metastatic disease that is refractoryXx_NEWLINE_xXMeasurable disease as defined by irRECIST. Patients with castrate-resistant prostate cancer can have measurable or evaluable disease. Patients with evaluable disease must have documented evidence of progressive disease as defined by any of the following:Xx_NEWLINE_xXMust have measurable or evaluable disease during the dose escalation phase (measurable disease is preferred for the expanded cohort after MTD is reached).Xx_NEWLINE_xXPatients must have evaluable disease on imagingXx_NEWLINE_xXPatients may have either measurable or non-measurable within 30 of days of registration; (lesions treated with radiation therapy must not be used as a target lesion); (Note: per Response Evaluation Criteria in Solid Tumors [RECIST] criteria version [v.] 1.1, measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension; non-measurable disease is defined as all other lesions, including small lesions [longest diameter < 10 mm or pathological lymph nodes with P10 to < 15 mm short axis] as well as truly non-measurable lesions; lesions considered truly non-measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, and inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques)Xx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXPrevious diagnosis of MM with objective evidence of measurable diseaseXx_NEWLINE_xXMust have at least 1 lesion with measurable diseaseXx_NEWLINE_xXMeasurable disease requirements on scans: PCNSL subjects should have at least one measurable extranodal brain lesion; PTL subjects should have at least 1 measurable extranodal lesion or nodal lesionXx_NEWLINE_xXAt least 1 measurable lesionXx_NEWLINE_xXHave evidence of measurable or unmeasurable diseaseXx_NEWLINE_xXMust have measurable disease as defined by irRECISTXx_NEWLINE_xXHave evaluable diseaseXx_NEWLINE_xXRadiographic or clinically measurable evidence of disease progressionXx_NEWLINE_xXMeasurable and/or evaluable disease per Lugano classificationXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients should have measurable metastatic disease in the liver, defined (for the purpose of this study) as at least 1 measurable lesion more than 2 cm in size and readily accessible to ultrasound (US) or computed tomography (CT)-guided biopsyXx_NEWLINE_xXMeasurable disease in at least one siteXx_NEWLINE_xXHave evaluable diseaseXx_NEWLINE_xXPatient must have at least one measurable untreated lesion as per modified RECIST criteria; measurable disease may include extrahepatic lesions; abdominal imaging should employ a “liver protocol” image capture technique; the following are not considered measurable lesions: bone lesions, ascites, and pleural effusions; prior radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), or transarterial chemoembolization (TACE) of non-target lesions is allowedXx_NEWLINE_xXMeasurable disease is not required\r\n* Patients who have measurable disease must have had X-rays, scans or physical examinations used for tumor measurement completed within 28 days prior to initial administration of drug\r\n* Patients must have non-measurable disease (such as nuclear medicine bone scans) and non-target lesions (such as PSA level) assessed within 28 days prior to initial administration of drug\r\n* Soft tissue disease that has been radiated within two months prior to registration is not assessable as measurable disease; soft tissue disease that has been radiated two or more months prior to registration is assessable as measurable disease provided that the lesion has progressed following radiation; patients must have at least one measurable lesion outside the previously irradiated region in order to be considered to have measurable disease\r\n* If PSA is the only indicator of disease and patients do not have any metastatic disease, PSA value must be 5.0 or higherXx_NEWLINE_xXPresence of measurable disease:Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed invasive breast cancer that is estrogen receptor positive (ER+) (> 1% staining) with radiographical or clinical evidence of metastatic disease \r\n* Measurable and/or non-measurable diseaseXx_NEWLINE_xXEvidence of evaluable diseaseXx_NEWLINE_xXPatients must have measurable disease; linear enhancement of leptomeningeal without measurable mass is excludedXx_NEWLINE_xXPatients must have measurable (>= 1.5 cm) or evaluable disease; baseline measurements and evaluations must be obtained within 21 days of registration to the study; abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging; measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least 1.5 cm in diameter on a CT scan will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possibleXx_NEWLINE_xXEvaluable disease in the phase I, and measurable disease for the phase II studyXx_NEWLINE_xXSubjects must have measurable disease per Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXRadiological assessment within 21 days prior to study entry demonstrating measurable disease that includes at least one pulmonary lesion >= 1 cm in greatest dimension that would be amenable to SBRT and at least one measurable lesion that would be outside of the SBRT treatment fieldsXx_NEWLINE_xXMeasurable disease is not required\r\n* Patients who have measurable disease must have had X-rays, scans or physical examinations used for tumor measurement completed within 28 days prior to initial administration of drug\r\n* Patients must have non-measurable disease (such as nuclear medicine bone scans) and non-target lesions (such as PSA level) assessed within 28 days prior to initial administration of drug\r\n* Soft tissue disease that has been radiated within two months prior to registration is not assessable as measurable disease; soft tissue disease that has been radiated two or more months prior to registration is assessable as measurable disease provided that the lesion has progressed following radiation; as the biology of previously irradiated tumors may be different from non-irradiated tumors, patients must have at least one measurable lesion outside the previously irradiated region in order to be considered to have measurable disease\r\n* If PSA is the only indicator of disease and patients do not have any metastatic disease, PSA value must be 5.0 or higherXx_NEWLINE_xXEvaluable disease: 1. During Part 1, evaluable disease is required; measurable disease per RECIST v1.1 is recommended but not required, 2. Subjects enrolled in Part 2 must demonstrate measurable disease per the disease-specific criteria.Xx_NEWLINE_xXMeasurable disease in at least 2 non-radiated sitesXx_NEWLINE_xXSubjects must have either measurable and/or evaluable diseaseXx_NEWLINE_xXPHASE I: Patients do not need to have measurable disease to enroll on phase IXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXEvidence of measurable or evaluable diseaseXx_NEWLINE_xXMeasurable disease, defined as >= 1.5 cm on imaging assessmentXx_NEWLINE_xXHave measurable disease based on RECIST 1.1; only cohort 9 and 10 can have evaluable disease (non-measureable lesions); tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions; patients may have bone metastatic disease evaluable according to tumor evaluation criteria best suitable and accepted for the tumor type evaluatedXx_NEWLINE_xXPresence of measurable or evaluable disease (unless patient has achieved a complete response (CR) following first-line antineoplastic therapy).Xx_NEWLINE_xXPatients without measurable or evaluable disease (unless patients achieved a complete response (CR) following 1st-line antineoplastic therapy).Xx_NEWLINE_xXAll patients must have measurable disease and tumors of sufficient sizes for biopsy; in general, liver and lung lesions should be at least 1.0 cm, and patients with lymph node-only disease should have lesions of >= 1.5 cm in shortest dimension; patients with disease confined to bone may be eligible if a measurable lytic defect is present; the study principal investigator (PI) is the final arbiter in questions related to measurability; patients with a three-dimensional mass or pelvic sidewall fixation on bladder examination under anesthesia are considered to have measurable diseaseXx_NEWLINE_xXMeasurable disease by physical examXx_NEWLINE_xXPresence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (at least one objectively bi-dimensionally measurable (nodal) lesion (>2 cm in its largest dimension by CT scan).Xx_NEWLINE_xXSubjects with measurable or non-measurable lesions.Xx_NEWLINE_xXPatients must have anticipated residual measurable disease after resection of target lesion(s) for TIL growthXx_NEWLINE_xXA minimum of one measurable lesion defined as:\r\n* Meeting the criteria for measurable disease according to irRECIST criteria\r\n* For patients with skin metastases, lesions selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)Xx_NEWLINE_xXPatients must have bi-dimensional measurable disease, as defined as radiographically apparent disease with the longest dimension of >= 1.5 cmXx_NEWLINE_xXPatients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN) and positive immunofixation test.Xx_NEWLINE_xXPatients with less than a 1.0 cm measurable residual disease after neoadjuvant anthracycline based chemotherapyXx_NEWLINE_xXPHASE II:\r\n* Patients without measurable disease by imaging\r\n* Patients with persistent platinum-refractory disease after primary therapyXx_NEWLINE_xXParticipants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma.Xx_NEWLINE_xXEvaluable diseaseXx_NEWLINE_xXPatients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.Xx_NEWLINE_xXMeasurable disease by RECIST criteria\r\n* For the lead-in, non-randomized portion of Part I, either measurable or evaluable disease is acceptable\r\n* For Part I, randomized portion, measurable disease is requiredXx_NEWLINE_xXSolid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.Xx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: the following do not qualify as measurable disease: \r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or cerebrospinal fluid (CSF) \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least 1 measurable lesionXx_NEWLINE_xXMeasurable disease (at least 1 lesion >= 1.5 cm in diameter) as detected by PET/CTXx_NEWLINE_xXAt least 1 lesion with measurable disease at baselineXx_NEWLINE_xXPHASE I: Patients may have measurable or non-measurable diseaseXx_NEWLINE_xXPHASE II: Patients may only have measurable diseaseXx_NEWLINE_xXPHASE I: Patients must have evaluable diseaseXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nAll patients must have measurable diseaseXx_NEWLINE_xXPatients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease; Note: measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable 10 mm soft tissue component that meets the measurability criteria per RECISTXx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXAt least 1.0 cm of measurable residual disease after neoadjuvant anthracycline-based chemotherapyXx_NEWLINE_xXEvaluable or measurable disease that meets the following criteria:Xx_NEWLINE_xXConfirmed measurable MM based on the following:Xx_NEWLINE_xXAll patients must have measurable or evaluable disease; in general, liver and lung lesions should be at least 1 cm, and patients with node-only disease should have lesions of >= 1.5 cm in greatest dimension; patients with disease confined to bone may be eligible if a measurable lytic defect is present or a serum marker is elevated (> 4 x upper limit of normal [ULN]); the principal investigator is the final arbiter in questions related to measurability; patients with a three-dimensional mass or pelvic sidewall fixation on bladder examination under anesthesia are considered to have measurable diseaseXx_NEWLINE_xXNon-measurable disease onlyXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXSubjects must have either measurable or evaluable diseaseXx_NEWLINE_xXNon-WM must have at least one bi-dimensionally measurable lesion (which has not been previously irradiated) according to the Lugano Classification. For patients with splenic MZL (Marginal-zone lymphoma) this requirement may be restricted to splenomegaly alone since that is usually the only manifestation of measurable disease.Xx_NEWLINE_xXPatients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN) and positive immunofixation test .Xx_NEWLINE_xXPatients must have either measurable or evaluable disease.Xx_NEWLINE_xXPatients must have measurable residual disease, defined as tumor that is measurable in two or three perpendicular diameters on MRI; for a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e visible on more than one slice)Xx_NEWLINE_xXSoft tissue disease that has been radiated within the two months prior to registration is not assessable as measurable disease; soft tissue disease that has been radiated two or more months prior to registration is assessable as measurable disease provided that the lesion has progressed following radiation; patients must have at least one measurable lesion outside the previously irradiated region in order to be considered to have measurable diseaseXx_NEWLINE_xXPatients enrolled in the main branch should have measurable disease; patients with a predominance of bone disease who have small, non-measurable or small measurable lesions other than bone, may be included per the principal investigator’s discretion, in the exploratory branch of the study for patients with bone metastases onlyXx_NEWLINE_xXSubject does not have measurable diseaseXx_NEWLINE_xXPatient must have either measurable or evaluable tumorXx_NEWLINE_xXAll patients must have measurable or evaluable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; if the patient has received prior radiation therapy one measurable lesion must be outside the irradiated field; lesions within an irradiated field will be followed as non-target lesions and considered evaluable; if the only site of measurable disease is within a previously irradiated field then 6 months must have elapsed between the completion of radiation therapy and entry on study to be considered measurable; if the specific diagnosis occurs radiologically as standard of care and a diagnostic procedure is too dangerous for any reason, subjects may be enrolled on study based on the presumptive radiographic diagnosisXx_NEWLINE_xXArms 1, 2, 3: patients should have clinically measurable or evaluable malignant diseaseXx_NEWLINE_xXAt least 1 measurable lesionXx_NEWLINE_xXMust have measurable disease (e.g., a tumor mass > 1 cm)Xx_NEWLINE_xXParticipants do not need to have measurable disease at the time of radiationXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXMeasurable disease by exam or CT scan, or for patients with cancer antigen (CA)-125 elevation or with microscopic residual but without measurable disease on imaging, willingness to undergo laparoscopy for evaluation of treatment effect if no radiographic progression after 6 treatment cyclesXx_NEWLINE_xXRadiologically measurable or clinically evaluable diseaseXx_NEWLINE_xXPatients must have measurable disease per RECIST criteria 1.1 performed within 28 days prior to enrollment. All other required tests to assess non-measurable disease must be performed within 42 days prior to enrollment.Xx_NEWLINE_xXPatients who have no measurable diseaseXx_NEWLINE_xXMeasurable disease prior to induction chemotherapyXx_NEWLINE_xXRadiologically measurable diseaseXx_NEWLINE_xXMeasurable or evaluable disease by RANO criteria (MRI) or Macdonald (CT) criteriaXx_NEWLINE_xXPatients do not need to have measurable disease at time of enrollment; patients with measurable disease must have stable disease by RECIST criteria on two scans at least 6 weeks apartXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPatient must have evaluable diseaseXx_NEWLINE_xXHave measurable disease. Patients must have clinically and/or radiographically documented measurable primary disease according to RECIST 1.1. At least one site of disease must be unidimensionally measurable. All radiology scans must be performed within 28 days prior to registrationXx_NEWLINE_xXEvidence of measurable or evaluable disease by clinical, radiographic, or laboratory assessmentXx_NEWLINE_xXMeasurable disease or non measurable disease bone lesions in the absence of measurable disease as per RECIST 1.1Xx_NEWLINE_xXEvidence of measurable (macroscopic) residual disease following hysterectomy and lymphadenectomyXx_NEWLINE_xXPatient must have evaluable disease; measurable disease is not requiredXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPresence of measurable disease that has been confirmed by histology or cytology.Xx_NEWLINE_xXClinically or radiographically evident structural disease; patients with measurable disease and those with only non-measurable (“non-target”) structural disease (according to modified Response Evaluation Criteria in Solid Tumors [RECIST] version [v] 1.1 criteria) are eligible;\r\nNOTE 1: Modification of the RECIST v1.1 measurable disease criteria includes a change in the definition of what is considered a measurable malignant lymph node; a malignant lymph node is considered measurable if any of the following apply:\r\n* It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy whole body scans acceptable) and it measures >= 1 cm in the long axis,\r\n* It is pathologically proven to be involved with thyroid cancer (by cytology or pathology) and it measures >= 1 cm in the long axis, or\r\n* Its short axis is >= 1.5 cm when assessed by computed tomography (CT) scan\r\nNOTE 2: Patients only with biochemical evidence of disease without structural evidence of cancer are not eligible for this studyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measureable disease which is defined as at least one measurable lesion that can be accurately measured in 2 planes; diffuse leptomeningeal involvement (\sugar coating\) that does not allow measurement of at least one lesion in 2 planes will not be considered measurable diseaseXx_NEWLINE_xXPatients with DSCRT are not required to have measurable or evaluable diseaseXx_NEWLINE_xXPatients with tumors other than DSRCT without measurable or evaluable disease will only be considered if they have < 20% chance of long term disease-free survivalXx_NEWLINE_xXThe Target Lesion must have measurable disease, defined as a unidimensionally measurable lesion ? 1.0 cm in longest diameter by helical CT; the maximum diameter of the Target Lesion shall be ? 4.9 cm.Xx_NEWLINE_xXMeasurable or evaluable disease: measurable disease in 2 dimensions on imaging studies performed within 4 weeks of starting treatmentXx_NEWLINE_xX2. Stage II-IV disease; T 2-4, N any, M0. Measurable disease is required with the following criteria: Measurable lesions can be accurately measured, with at least one diameter >\\= 1.0 cm by spiral CT scan or MRI. Lesions can be bidimensionally measurable or unidimensionally measurable. Every effort should be made to measure lesions in two dimensions. Measurable disease is present if the patient has one or more measurable lesions. Non-measurable lesions/disease are all other lesions, including small lesions (those with measurements < 2.0 cm; or < 1.0 cm with spiral CT).Xx_NEWLINE_xXThe presence of measurable disease meeting the following criteria:Xx_NEWLINE_xXMeasurable disease;Xx_NEWLINE_xXHave measurable disease by at least 1 of the following measurements:Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease.Xx_NEWLINE_xXHas evaluable or measurable disease for response assessmentXx_NEWLINE_xXPatients with just one measurable or evaluable tumour lesion that has been resected or irradiated prior to their enrolment in the studyXx_NEWLINE_xXCriteria 3 Measurable disease with at least 1 of the following assessed within 21 days prior to randomization:Xx_NEWLINE_xXSubjects must have at least one measurable lesionXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease on MRI performed within 14 days prior to registration.Xx_NEWLINE_xXPresence of measurable or evaluable disease.Xx_NEWLINE_xXPatients without measurable or evaluable disease.Xx_NEWLINE_xXMeasurable or non-measurable metastatic diseaseXx_NEWLINE_xXPatients must have measurable disease (using modified Severity-Weighted Assessment Tool [mSWAT]) and/or use of indicator lesions must be designated prior to study enrollment (from imaging); measurable disease upon physical exam with a negative scan is acceptableXx_NEWLINE_xXPatient has measurable disease.Xx_NEWLINE_xXMeasurable disease by CT or MRI.Xx_NEWLINE_xXPatients must have at least one site of measurable diseaseXx_NEWLINE_xXPatient with measurable progressive disease defined by at least one of the following two measurements:Xx_NEWLINE_xX107 Radiographically measurable disease with a clearly demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension. In the dose exploration phase in case disease is not radiographically measurable PET positivity (ie, Deauville ?4) instead is acceptable.Xx_NEWLINE_xXPrior radiation performed to areas of measurable disease ? four weeks of study entry unless there is documented evidence of disease progression.Xx_NEWLINE_xXMeasurable disease at screening as defined per protocol.Xx_NEWLINE_xXFor Part 1, evaluable or measurable diseaseXx_NEWLINE_xXMeasurable disease as per IMWG response criteriaXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXRadiographically measurable disease in the CNS documented ? 3 weeks prior to starting E6201 treatmentXx_NEWLINE_xXMeasurable disease by CT or MRI, but with no single lesion measuring more than 10.0 cmXx_NEWLINE_xXNo evidence of distant metastases and measurable disease (> 1.5 cm).Xx_NEWLINE_xXSubjects must have either measurable or evaluable diseaseXx_NEWLINE_xXPresence of measurable disease as defined by: presence of immunoglobulin M (IgM) paraprotein, measurable lymphadenopathy on imaging studies and/or physical exam, and/or bone marrow infiltration > 10%Xx_NEWLINE_xXPRE-REGISTRATION: Documentation of measurable or evaluable non-measurable disease.Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measurable FDG-avid disease defined by standard criteria (Lugano 2014) and a minimum of 1.0 cm in diameterXx_NEWLINE_xXPatients should in general have bi-dimensional measurable disease using the Cheson criteria (measurable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension) (bone marrow or gastrointestinal [GI] only involvement is acceptable).Xx_NEWLINE_xXMeasurable disease is not required for enrollmentXx_NEWLINE_xXMeasurable disease is not required:\r\n* Patients who have measurable disease must have had X-rays, computed tomography (CT) scans or physical examinations used for tumor measurement completed within 28 days prior to initial administration of drug\r\n* Patients must have non-measurable disease (such as nuclear medicine bone scans) and non-target lesions (such as PSA level) assessed within 28 days prior to initial administration of drug\r\n* Soft tissue disease that has been radiated within two months prior to registration is not assessable as measurable disease; soft tissue disease that has been radiated two or more months prior to registration is assessable as measurable disease provided that the lesion has progressed following radiation; as the biology of previously irradiated tumors may be different from non-irradiated tumors, patients must have at least one measurable lesion outside the previously irradiated region in order to be considered to have measurable disease\r\n* If PSA is the only indicator of disease without any evidence of metastasis, PSA value must be 5.0 or higherXx_NEWLINE_xXHave measurable disease based on immune-related response criteria (irRC)Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice; Note: The following do not qualify as measurable disease:\r\n* Malignant fluid collections (e.g., ascites, pleural effusions)\r\n* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\r\n* Previously radiated lesions that have not demonstrated clear progression post radiation\r\n* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMust have at least 1 lesion with measurable diseaseXx_NEWLINE_xXHave measurable disease based on irRECIST 1.1Xx_NEWLINE_xXDocumentation of disease:\r\n* Histologic documentation: histologically proven intracranial meningioma as documented by central pathology review\r\n* Molecular documentation: presence of SMO, PTCH1 or NF2 mutation in tumor sample as documented by central laboratory\r\n* Progressive OR residual disease, as defined by the following: \r\n** Residual measurable disease: residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions\r\n** Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 12 months\r\n** Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; at least 24 weeks must have elapsed from completion of radiation to registrationXx_NEWLINE_xXMeasurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins; multifocal disease is allowedXx_NEWLINE_xXPatients must have measurable disease as per appropriate guidelines:\r\n* Solid tumors: by RECIST v1.1\r\n* Lymphoma: patient has at least one measurable nodal lesion (>= 2 cm) according to Lugano classification; if the patient has no measurable nodal lesions >= 2 cm in the long axis at screening, then the patient must have at least one measurable extra-nodal lesionXx_NEWLINE_xXDisease status: phase I: patients with refractory solid tumors must have evaluable disease, patients with NF1 PN must have measurable disease, patients with refractory leukemia must have M2 or M3 bone marrow; phase II: patients must have measurable disease; phase II temporarily suspended as requested by the FDA due to IND Safety Report of 07 October 2016Xx_NEWLINE_xXMeasurable disease defined by 1 or more of the following:Xx_NEWLINE_xXAn additional eligibility requirement for phase II study includes the presence of radiographically measurable disease with the exception of MIBG-positive NB or NB with bone marrow involvement:\r\n* Measurable disease is defined as the presence of at least one solid lesion on MRI or CT scan that can be accurately measured with the longest diameter of at least 10 mm in at least one dimension\r\n* Patients with NB who do not have measurable soft tissue disease but have MIBG-positive evaluable skeletal disease are eligible for phase II study\r\n* Patients with NB who have evidence of tumor cells in bone marrow are eligible for phase II studyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients with evaluable disease will be eligibleXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHave measurable disease based as defined by at least one lesion that can be measured in least 2 perpendicular dimensions and measures at least 1.5 cm in its long axisXx_NEWLINE_xXPatients must have measurable disease in the serum and/or urineXx_NEWLINE_xXParticipants may have either measurable or non-measurable disease, but in all cases eligible patients must have disease that can be clinically evaluated for improvement or progressionXx_NEWLINE_xXHave measurable disease evident on radiographs (preferred) or clinical examination; for this protocol, measurable disease is defined as at least one evaluable tumor that is at least 10 mm in longest dimensionXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXHave measurable disease based on RECIST 1.1., or detectable disease; lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXSubjects should have measurable or evaluable diseaseXx_NEWLINE_xXPatients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to Step 2 re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to Step 2 re-registration; all disease must be assessed and documented on the baseline tumor assessment form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registrationXx_NEWLINE_xXHistologically proven malignant solid tumors with measurable disease (except lymphomas)Xx_NEWLINE_xXPatients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registrationXx_NEWLINE_xXPatients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 2 re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to step 2 re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registrationXx_NEWLINE_xXFor escalation cohorts, if no measurable disease is present, then at least one predominantly lytic bone lesion must be presentXx_NEWLINE_xXPatients must have evidence of metastatic disease (non measurable disease is eligible)Xx_NEWLINE_xXPatients may have additional measurable and/or non-measurable but radiographically visible metastatic lesions (e.g. bone metastases)Xx_NEWLINE_xXPatients with neuroblastoma who do not have measurable disease but have MIBG-avid evaluable disease are eligibleXx_NEWLINE_xXMeasurable disease requiredXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXAt least one lesion in the brain that is measurable, which is defined as >= 5 x 5 mm; (prior craniotomy and surgical resection is allowed, as long as there is at least one remaining measurable lesion in the brain)Xx_NEWLINE_xXPatients must have at least one 1.5 cm bidimensional measurable lesionXx_NEWLINE_xXPatients must have measurable disease; cutaneous lesions measuring at least 1 cm will be considered measurable; baseline CT or magnetic resonance imaging (MRI) scans of measurable disease sites must be performed within 4 weeks of study entryXx_NEWLINE_xXCastration resistant prostatic adenocarcinoma; subjects must have current or historical evidence of disease progression despite castrated level of testosterone (< 50 ng/dL) achieved by orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy; disease progression has to be demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease as defined below:\r\n* PSA: two consecutive rising PSA values, at least 7 days apart\r\n* Measurable disease: >= 20% increase in the sum of the longest diameters of all measurable lesions or the development of any new lesions; the change will be measured against the best response to castration therapy or against the pre-castration measurements if there was no response\r\n* Non-measurable disease: \r\n** Soft tissue disease: the appearance of 1 or more lesions, and/or equivocal worsening of non-measurable disease when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response\r\n** Bone disease: appearance of 2 or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response; increased uptake of pre-existing lesions on bone scan does not constitute progressionXx_NEWLINE_xXPatients must have evaluable diseaseXx_NEWLINE_xXResidual measurable disease after resection of target lesion(s) for TIL growthXx_NEWLINE_xXRadiographically measurable disease by RECIST version 1.1 in at least one site not previously treated with chemoembolization, radioembolization, or other local ablative procedures (i.e. must have at least one measurable target lesion, either within the liver or in a measurable metastatic site); a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptableXx_NEWLINE_xXResidual measurable disease after resection of target lesion(s) for TIL growthXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysisXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease\r\n* Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion >= 1 cm and =< 7 cm\r\n* DCIS must be visible on MRI based on central review\r\n* Patients with palpable DCIS or adenopathy are not eligible to participate\r\n* Patients with multifocal or bilateral disease are eligibleXx_NEWLINE_xXPatients may have measurable or evaluable diseaseXx_NEWLINE_xXMeasurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable; any tumor mass > 1 cm is acceptable; lesions that are considered non-measurable include the following:\r\n* Bone lesions\r\n* Leptomeningeal disease\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Inflammatory breast disease\r\n* Lymphangitis cutis/pulmonis\r\n* Bone marrow involvement (involvement by non-Hodgkin lymphoma should be noted)Xx_NEWLINE_xXMeasurable or non-measurable tumor parameter(s); non-measurable tumor parameters are defined as not having bidimensional measurements (e.g., gastric or marrow involvement), but can be followed for response by other diagnostic tests such as gallium, positron emission tomography (PET) imaging, and/or bone marrow biopsyXx_NEWLINE_xXMeasurable unresectable melanoma at least 1 measurable lesion based on Immune-related Response Criteria (irRC)Xx_NEWLINE_xXPatients must have measurable advanced disease, that is not resectable by surgery; all sites must be assessed within 4 weeks prior to randomizationXx_NEWLINE_xXDisease status:\r\n* Phase 1 (Part A): Patients must have either measurable and/or evaluable disease\r\n* Phase 2 (Part B): Patients with neuroblastoma must have proven ALK+ disease with either measurable and/or evaluable disease as indicated below:\r\n** Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan or X-ray obtained within 2 weeks prior to study enrollment\r\n** Evaluable tumor by meta-iodobenzyl guanidine I 123 (MIBG) scan and/or bone marrow involvement with tumor cells seen on routine morphology \r\n* Phase 2 (Part C): Patients must have proven ALK+ disease with either measurable or evaluable diseaseXx_NEWLINE_xXParticipants with measurable disease or non-measurable disease are eligible. Participants may or may not have cancer-related symptoms.Xx_NEWLINE_xXPatients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollmentXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXHas measurable diseaseXx_NEWLINE_xXPrior stereotactic radiotherapy (SRT) and prior excision of up to 3 melanoma brain metastases is permitted if there has been complete recovery, with no neurologic sequelae, and measurable lesions remain. Growth or change in a lesion previously irradiated will not be considered measurable. Regrowth in cavity of previously excised lesion will not be considered measurable. lesions or prior excision must have occurred ? 3 weeks before the start of dosing for this studyXx_NEWLINE_xXEvaluable disease;Xx_NEWLINE_xXMeasurable disease by CT or MRIXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXSoft tissue disease progression defined by RECIST 1.1 at Screening or ? 28 days of C1D1. Measurable disease is not required for entry. Lymph nodes ? 1.5cm (short axis) are considered measurable disease (PCWG3)Xx_NEWLINE_xXMeasurable (target) disease.Xx_NEWLINE_xXOnly evidence of disease is non measurable at study entry.Xx_NEWLINE_xXPatients must have either measurable or evaluable limited-stage DLBCL          \r\n* Patients rendered free of measurable or evaluable disease by virtue of biopsy (resection) are also eligible; NOTE: if patient has measurable disease it must be documented on the Lymphoma Baseline Tumor Assessment Form\r\n* All measurable disease must be assessed within 28 days prior to registration\r\n* Patients with non-measurable disease with or without measurable disease must have all non-measurable disease assessed within 42 days prior to registrationXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXHas measurable diseaseXx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXMeasurable disease at time of enrollmentXx_NEWLINE_xXAt least a single measurable lesion. Phase II patients onlyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease of MM as defined by at least ONE of the following:Xx_NEWLINE_xXMeasurable disease or evaluable disease with relevant tumor marker elevation.Xx_NEWLINE_xXPatients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment FormXx_NEWLINE_xXPatients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to re-treatment registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to re-treatment registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to RE-TREATMENT registrationXx_NEWLINE_xXMeasurable disease based on investigator's assessments meeting the following criteria:Xx_NEWLINE_xXHas measurable disease.Xx_NEWLINE_xXSubject must have either measurable disease or bone only non measurable disease, according to RECIST1.1Xx_NEWLINE_xXPatients with measurable disease defined as at least one of the following:Xx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXNon-measurable disease: includes patients with symptomatic ascites or pleural effusions, lesions that do not meet RECIST criteria or biopsy proven recurrence; patients with clinically evident non-measurable disease must have either an elevated CA125 or histological confirmation of recurrenceXx_NEWLINE_xXMust have evaluable or measurable diseaseXx_NEWLINE_xXmeasurable lymphadenopathyXx_NEWLINE_xXMeasurable disease at screeningXx_NEWLINE_xXThe extramedullary plasmacytoma (EMP) sub-group, must have radiologically measurable EMP disease (soft tissue or bone related) that is amenable to biopsy and does not need to have measurable disease.Xx_NEWLINE_xXMeasurable disease per the IMWG response criteriaXx_NEWLINE_xXPatients with a history of measurable disease as defined by RECIST criteria or bone only disease are eligible; Note: those patients with non-measurable disease and bone metastases are eligibleXx_NEWLINE_xXPatients with either measurable disease as defined by RECIST criteria or bone only disease are eligible; Note: those patients with both non-measurable disease and bone metastases are eligible\r\n* Non-measurable bone only disease: Non-measurable bone only disease may include any of the following: blastic bone lesions, lytic bone lesions without a measurable soft-tissue component, or mixed lytic-blastic bone lesions without a measurable soft-tissue component\r\n* Lytic bone lesions, with an identifiable soft tissue component, evaluated by computed tomography (CT) or magnetic resonance imaging (MRI), can be considered as measurable lesions if the soft tissue component otherwise meets the definition of measurability previously describedXx_NEWLINE_xXMust have measurable diseaseXx_NEWLINE_xXAll sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable diseaseXx_NEWLINE_xXFor Dose Escalation (Part A): Have measurable or nonmeasurable disease.Xx_NEWLINE_xXFor Parts B, C, D, E and F: Have measurable disease or reliable biomarker measure.Xx_NEWLINE_xXSubjects must have measurable lesions (at least one target lesion measuring 2 cm in diameter) by computerized tomography (CT) scan, and/or measurable lymphoma cutaneous lesions of any sizeXx_NEWLINE_xXEvaluable diseaseXx_NEWLINE_xXFluorodeoxyglucose-avid disease by positron emission tomography and measurable disease greater than 1.5cm diameterXx_NEWLINE_xXMeasurable disease, as defined by the 2014 Lugano Classification.Xx_NEWLINE_xXMeasurable disease defined by at least ONE of the following:Xx_NEWLINE_xXMeasurable disease by RANO criteria at progression;Xx_NEWLINE_xXPatient must have measurable disease or detectable (non-measurable) disease: Measurable disease will be defined by RECIST 1.1.Xx_NEWLINE_xXMeasurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable; any tumor mass > 1 cm is acceptable; lesions that are considered non-measurable include the following:\r\n* Bone lesions (lesions if present should be noted)\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Lymphangitis cutis/pulmonis\r\n* Bone marrow (involvement by SLL or CLL should be noted)Xx_NEWLINE_xXMeasurable disease or non-measurable disease; extent of resection: patients with complete resection, partial resection, or biopsy are eligibleXx_NEWLINE_xXSubject should have stable disease for at least 6 months on the current regimen with the last 2 scans taken at least 6 weeks apart; measurable disease is not requiredXx_NEWLINE_xXAt least one radiographically measurable lesionXx_NEWLINE_xXPatients may have either measurable or non-measurable disease, but in all cases eligible patients must have disease that can be clinically evaluated for improvement or progressionXx_NEWLINE_xXPatients must have measurable disease; disease in previously irradiated sites is considered measurable if there is clear disease progression following radiation therapyXx_NEWLINE_xXPatient has measurable disease defined as any of the following:Xx_NEWLINE_xXMeasurable disease criteria:Xx_NEWLINE_xXFor MM, Diffuse large B-cell lymphoma (DLBCL): Subjects must have disease that is objectively measurable, measurable levels of myeloma paraprotein in serum (> 0.5 g/dL) or urine (> 0.2 g excreted in a 24-hour collection sample) for MM and measurable disease by Internatonal Working Group (IWG) for NHL (with at least one measurable lesion's longest diameter ? 2cm).Xx_NEWLINE_xXAt least one measurable lesion according to the International Working Group Response Criteria for Lymphomas; there must be measurable lymphadenopathy to follow with serial exam and/or imagingXx_NEWLINE_xXMust have at least 1 lesion with measurable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXAt least one measurable lesionXx_NEWLINE_xXHistological confirmation of disease with documented disease relapse after the last therapy requiring treatment per the treating physician. Participants with lymphoma must have at least 1 measurable site of disease (Part 2 only). In addition, B-cell malignancy disease-specific criteria specified in the protocol must also be metXx_NEWLINE_xXMeasurable disease, as defined by the International Harmonization ProjectXx_NEWLINE_xXPresence of at least 2 measurable lesionsXx_NEWLINE_xXMeasurable or non-measurable disease will be allowed, but only those with measurable disease will be evaluable for the response rate endpointXx_NEWLINE_xXPatient has at least one measurable lesion (>= 2 cm) according to Cheson criteriaXx_NEWLINE_xXPatient must have either measurable disease or If no measurable disease is present, then at least one predominantly lytic bone lesionXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHave either measurable disease or nonmeasurable bone-only diseaseXx_NEWLINE_xXFor patients with neither LM nor measurable BM: At least one measurable extracranial lesion. For patients with measurable BM but without LM: at least one measurable intracranial lesionXx_NEWLINE_xXAt least one bi-dimensional measurable lesionXx_NEWLINE_xXPatients must have measurable metastatic melanomaXx_NEWLINE_xXMeasurable or evaluable disease.Xx_NEWLINE_xXMeasurable disease defined as one or both of the followingXx_NEWLINE_xXBidimensional measurable diseaseXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have at least one objective measurable disease parameter; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging; measurable disease in the liver is required if the liver is the only site of lymphoma; if the only radiographically assessable disease is splenomegaly (without discrete measurable nodules), the patient can be enrolled, but for such patients CR cannot be differentiated from PR, while the spleen will be considered nodal with respect to criteria for progressive disease (PD)Xx_NEWLINE_xXMust have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease.Xx_NEWLINE_xXParticipant has measurable and/or non-measurable diseaseXx_NEWLINE_xXMeasurable disease, requiring treatmentXx_NEWLINE_xXMeasurable disease by RECISTv1.1 criteriaXx_NEWLINE_xXBoth measurable as well as non-measurable disease will be allowedXx_NEWLINE_xXSubjects may have measurable or non measurable but evaluable disease; subjects with surgically resected locally advanced or metastatic disease at high risk of relapse are also eligibleXx_NEWLINE_xXBi-dimensionally measurable disease (> 2.0 cm).Xx_NEWLINE_xXPatient has at least one measurable lesion (>= 2 cm) according to Lugano classificationXx_NEWLINE_xXMeasurable disease with >= 1 target lesionXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have measurable or non-measurable disease documented by computed tomography (CT) scan; measurable disease must be assessed within 28 days prior to registration; non-measurable disease must be assessed within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT must not be used to document measurable disease unless it is of diagnostic quality; all disease must be assessed by RECIST and modified RECIST criteriaXx_NEWLINE_xXStage IV disease (measurable disease NOT required)Xx_NEWLINE_xXPatients with measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least 1.5 cm in diameter on the CT portion of a PET/CT or CT scan or magnetic resonance imaging (MRI) (if appropriate) will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possibleXx_NEWLINE_xXMeasurable disease on cross section imaging that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensionsXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHave measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)Xx_NEWLINE_xXMeasurable disease: measurable by gadolinium MRI scanXx_NEWLINE_xXPrior chemoembolization, radiofrequency ablation, or radiation to the liver is allowed as long as the patient has measurable disease outside of the treated area or measurable progression at the site of the treated areaXx_NEWLINE_xXPatients must have radiographically measurable diseaseXx_NEWLINE_xXMeasurable disease with at least 1 of the following assessed within the 21 days prior to randomization:Xx_NEWLINE_xXMeasurable disease by CT or MRIXx_NEWLINE_xXIf no measurable disease is present, then at least one predominantly lytic bone lesion must be presentXx_NEWLINE_xXPatients affected by WM, who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment, must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN)and positive immunofixation test.Xx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXMeasurable disease with greatest diameter ? 10 mmXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHave measurable disease consisting of a minimal volume of 1 cm^3Xx_NEWLINE_xXMeasurable disease (NHL: At least 1 measurable site of disease [>1.5 centimeter [cm] in the long axis regardless of short axis measurement or >1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensions])Xx_NEWLINE_xXAt least 1 measurable lesion at baseline;Xx_NEWLINE_xXPatients are required to have evaluable diseaseXx_NEWLINE_xXIn addition to index lesion, there are >= 1 measurable lesion(s)Xx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have bi-dimensional measurable disease (measurable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension); patient with leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligibleXx_NEWLINE_xXHave measurable disease based on irRECIST (Safety expansion only)Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXMeasurable disease (at least one lesion that is 1.5 cm in the longest diameter on cross?sectional imaging and measurable in 2 perpendicular dimensions per computed tomography [CT]) for non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) subjects; for myeloma patients measurable disease is defined as presence of more than 5% plasma cells in the bone marrow aspiration and/or presence of monoclonal gammopathy in serum protein electrophoresis (SPEP) and immunofixationXx_NEWLINE_xXNon-measurable or measurable diseaseXx_NEWLINE_xXFOR EXPANSION PHASE ONLY: For the expansion phase, patients must have measurable disease accessible for biopsyXx_NEWLINE_xXAt least 1 measurable lesion at baselineXx_NEWLINE_xXPresence of measurable or evaluable diseaseXx_NEWLINE_xXMeasurable disease defined as serum monoclonal IgM >0.5 g/dL.Xx_NEWLINE_xXMeasurable disease; note: disease that is measurable by physical examination only is not eligibleXx_NEWLINE_xXThe patient has measurable diseaseXx_NEWLINE_xXParticipants must have measurable disease (lymphocytosis > 5,000/ul, or palpable or CT measurable lymphadenopathy > 1.5 cm, or bone marrow involvement > 30%)Xx_NEWLINE_xXMeasurable and non-measurable disease will be allowedXx_NEWLINE_xXSubjects must have ? 1 measurable disease sitesXx_NEWLINE_xXHave either measurable disease or nonmeasurable bone only diseaseXx_NEWLINE_xXa.For Escalation Phase: At least one lesion (measurable and/or non-measurable) b.For Expansion Phase: At least one measurable lesion.Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable disease (subjects with elevation of tumor marker with no evidence of disease on imaging or exam are not eligible)Xx_NEWLINE_xXPatients must have measurable disease at baselineXx_NEWLINE_xXPHASE I: Either measurable or evaluable disease is allowedXx_NEWLINE_xXPatients must have at least 1 measurable tumorXx_NEWLINE_xXMeasurable disease as indicated by 1 or more of the following:Xx_NEWLINE_xXEvaluable disease in the Phase I, and measurable disease for the Phase IIXx_NEWLINE_xXMeasurable disease at the time of enrollmentXx_NEWLINE_xXAll patients must have measurable residual disease defined as tumor measurable in two perpendicular diameters on magnetic resonance imaging (MRI); measurements are required for both the solid and cystic componentsXx_NEWLINE_xXPatient must have either: • Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria (Tumor lesions previously irradiated or subjected to other locoregional therapy will only be considered measurable if disease progression at the treated site after completion of therapy is clearly documented). OR • If no measurable disease is present, then at least one predominantly lytic bone lesion must be present (Patients with no measurable disease and only one predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).Xx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXAt least one measurable untreated lesionXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXSubjects must have clinically or radiographically evident measurable disease at nodal stationsXx_NEWLINE_xXMeasurable disease is required unless patient is post-operative and in that case patient can have no evidence of diseaseXx_NEWLINE_xXPatients may have measurable or non-measurable disease. x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registration; (expansion – patients must have measurable disease)Xx_NEWLINE_xXPatients may have measurable or non-measurable disease; x-rays and/or scans for disease assessment of measurable disease must have been completed within 28 days prior to registration; non-measurable disease must also be assessed within 28 days prior to registrationXx_NEWLINE_xXEvidence of at least one measurable lesion as detected by radiological or photographic methodsXx_NEWLINE_xXPatients must have measurable or non-measurable disease; all measurable lesions must be assessed (by physical examination, computed tomography [CT], or magnetic resonance imaging [MRI] scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXPatients must have measurable disease; all measurable lesions must be assessed (by physical examination, CT, or MRI scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)Xx_NEWLINE_xXPatients must have measurable disease in the brain, defined as at least 1 lesion measuring >= 5 mm on imagingXx_NEWLINE_xXPresence of measurable disease meeting the following criteria:Xx_NEWLINE_xXMeasurable disease of at least 1.5 cm as documented by radiographic techniqueXx_NEWLINE_xXMeasurable disease as specified in study protocolXx_NEWLINE_xXRadiological evidence for progressive disease (measurable or non-measurable) within 12 months prior to registration; patients who have received anti-tumor therapy during the past 12 months (including octreotide analogs) must have had radiological documentation of progression of disease while on or after receiving therapyXx_NEWLINE_xXPatients with measurable or evaluable disease are eligibleXx_NEWLINE_xXThey must have recurrent melanoma with measurable or evaluable sites of disease, 1.0 cm or larger, in order to assess the response to treatment by the immune-related response criteria (irRC)Xx_NEWLINE_xXPatients must have measurable disease, documented by clinical and radiographic criteriaXx_NEWLINE_xXFluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CTXx_NEWLINE_xXPatients must have measurable lesionsXx_NEWLINE_xXRecurrent NSCLC: Defined as the re-appearance of measurable disease, or the appearance of new measurable disease by RECIST Criteria after prior successful treatment or complete response.Xx_NEWLINE_xXEvidence of at least one measurable lesion as detected by radiological or photographic methodsXx_NEWLINE_xXEvaluable or measurable diseaseXx_NEWLINE_xXEXPANSION PHASE ONLY: Evaluable or measurable disease with the largest nodule measuring less than 5 cm in greatest dimension by radiographic imaging after debulking procedureXx_NEWLINE_xXA histologically confirmed rectal cancer with measurable or evaluable disease on imaging or endoscopyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXSubjects must have at least 1 measurable lesion.Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one tumor that is measurableXx_NEWLINE_xXMeasurable or evaluable disease, as defined in 2008 Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXParticipants are not required to have measurable disease but must have an accessible tumor to biopsyXx_NEWLINE_xXMeasurable or non-measurable disease will be allowedXx_NEWLINE_xXPatients must have evaluable disease for responseXx_NEWLINE_xXMeasurable nodal disease by computed tomographyXx_NEWLINE_xXPresence of at least 1 measurable site of disease.Xx_NEWLINE_xXMust have had measurable disease, defined by at least 1 of the following 3 measurements:Xx_NEWLINE_xXPatients must have measurable residual disease, defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI); for a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e. visible on more than one slice)Xx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXMeasurable disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptableXx_NEWLINE_xXNon-measurable disease: all other lesions, including small lesions (less than 1.0 x 1.0 cm) and truly non-measurable lesions; lesions that are considered non-measurable include the following:\r\n* Bone lesions (lesions if present should be noted)\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Lymphangitis cutis/pulmonis\r\n* Bone marrow (involvement by Hodgkin’s lymphoma should be noted)Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement)Xx_NEWLINE_xXRetinoblastoma-positive, histologically proven CRC with measurable diseaseXx_NEWLINE_xXIt is anticipated that patients who have intracranial disease amenable to surgery will have measurable CNS disease prior to study entry and to resection; however, this is not an eligibility requirement; measurable disease is also not required to continue on protocol subsequent to surgical resectionXx_NEWLINE_xXPatients must have measurable disease; patients with a diagnosis of neuroblastoma with Iobenguane (MIBG) avid disease only are permitted to enroll on this studyXx_NEWLINE_xXPatients must have measurable or non-measurable (evaluable) disease recurrence\r\n* Recurrence must be documented based on a combination of clinical and imaging parameters, consistent with routine clinical practice, with or without histologic confirmation\r\n* Patients may have had any number of relapses and be eligible for the studyXx_NEWLINE_xXPatients must have bi-dimensional measurable disease within 60 days prior to starting treatment (at least 1.5 cm); patients with non-measurable disease in addition to measurable disease must have been assessed within 60 days prior to starting treatmentXx_NEWLINE_xXPatient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension.Xx_NEWLINE_xXMeasurable disease, defined by the revised lymphoma criteria (Cheson 2007)Xx_NEWLINE_xXDuring the dose expansion part of the study patients must have measurable disease defined by at least 1 of the following 2 measurements:Xx_NEWLINE_xXAt least 1 measurable target brain lesion >0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions >0.3 cmXx_NEWLINE_xXMeasurable disease on cross sectional imaging of at least 1 cmXx_NEWLINE_xXFor Parts A and G: Have measurable or nonmeasurable diseaseXx_NEWLINE_xXFor Parts B, C, D, E and F: Have measurable diseaseXx_NEWLINE_xXPatients must have measurable disease:Xx_NEWLINE_xXPatients must have measurable radiographic disease; patients with previous complete resection are only eligible if there is measurable radiographic disease which is clearly felt to represent locally recurrent diseaseXx_NEWLINE_xXPatients with recurrence who undergo resection and are left without measurable or evaluable disease are eligibleXx_NEWLINE_xXMeasurable disease is not required for this study, since the primary endpoint is complete pathologic responseXx_NEWLINE_xXPresence of measurable diseaseXx_NEWLINE_xXCertain type(s) of non-measurable lesion(s), if the only one(s).Xx_NEWLINE_xXBoth measurable and non-measurable disease are allowedXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXIf the lesion(s) to be treated are soft-tissue or lymph nodes, unidimensionally measurable disease is required; bone & spine lesions are eligible even if considered non-measurable; measurable disease is defined as:\r\n* >= 10 mm for soft-tissue lesions\r\n* >= 15 mm on the short axis of lymph nodesXx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXHave measurable disease.Xx_NEWLINE_xXPatient has at least one measurable nodal lesion (>= 2.0 cm)Xx_NEWLINE_xXEvidence of objective disease. A measurable lesion is not necessary.Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease;Xx_NEWLINE_xXPatients with measurable and non-measurable disease are eligible. Patients may or may not have cancer-related symptoms.Xx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXParticipants do not need to have measurable disease; most patients will not have measurable disease at the time of treatmentXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPresence of measurable diseaseXx_NEWLINE_xXEvaluable/measurable disease Non-CLL B-cell malignancies (Arms A, C, and D):Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease; measurable disease is defined as that which can be measured in at least one dimension as >= 20 mm with conventional techniques, or >= 10 mm by high resolution imaging; disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurableXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXAll patients must have measurable or evaluable disease. In general, liver and lung lesions should be at least 1 cm, and patients with node-only disease should have lesions of >/= 1.5 cm in greatest dimension. Patients with disease confined to bone may be eligible of a measurable lytic defect is present or a serum marker is elevated (>4 x ULN). The Study Chairman is the final arbiter in questions related to measurability. Patients with a three-dimensional mass or pelvic sidewall fixation on bladder examination under anesthesia are considered to have measurable disease.Xx_NEWLINE_xXPresence of measurable tumorXx_NEWLINE_xXAt least one measurable lesionXx_NEWLINE_xXSubjects with bone or skin as the only site of measurable diseaseXx_NEWLINE_xXMeasurable (target) disease.Xx_NEWLINE_xXNon-Measurable M Protein (serum or urine) and measurable sFLC (< 100 mg/mL)Xx_NEWLINE_xXAt least 1 measurable site of diseaseXx_NEWLINE_xXSubjects must have either measurable disease or bone-only non-measurable disease, evaluable according to RECIST 1.1Xx_NEWLINE_xXRadiographically measurable or evaluable diseaseXx_NEWLINE_xXPresence of measurable lymphadenopathyXx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXPatients with T-cell LL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis. Patients with T-cell LL enrolled in the phase I dose-escalation study are not required to have measurable disease; however, patients enrolled in the phase II cohort expansion at the MTD must have measurable disease.Xx_NEWLINE_xXThe participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part 1 onlyXx_NEWLINE_xXMeasurable disease defined by at least 1 lesion >= 1 cmXx_NEWLINE_xXMeasurable disease according to the Lugano ClassificationXx_NEWLINE_xXMeasurable disease.Xx_NEWLINE_xXMeasurable (target) disease.Xx_NEWLINE_xXSubjects need to have evaluable disease (measurable or not measurable).Xx_NEWLINE_xXHistologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesionXx_NEWLINE_xXMust have measurable disease defined as:Xx_NEWLINE_xXMust have ?1 measurable disease sites as defined by standard Lugano classification.Xx_NEWLINE_xXmeasurable disease at screening and documented progression within the past 6 weeksXx_NEWLINE_xXDuring the escalation phase of the protocol, patients may have evaluable or measurable disease; during the expansion phase of the protocol, patients must have 1) measurable disease, 2) disease amenable to biopsy and 3) willingness to undergo pre- and post-treatment biopsiesXx_NEWLINE_xXMust have measurable disease (e.g., a tumor mass > 1 cm)Xx_NEWLINE_xXSubjects in Group 3 are not required to have measurable disease but must have cytologic confirmation of leptomeningeal diseaseXx_NEWLINE_xXMust have measurable disease for Part A, measurable disease or non-measurable disease for Part BXx_NEWLINE_xXRadiographically measurable or evaluable diseaseXx_NEWLINE_xXRadiographically measurable or evaluable diseaseXx_NEWLINE_xXRadiographically measurable or evaluable disease.Xx_NEWLINE_xXMeasurable or evaluable disease based on IWCLL criteriaXx_NEWLINE_xXPresence of measurable lymphadenopathyXx_NEWLINE_xXMeasurable disease of at least 1.5 cmXx_NEWLINE_xXPatients must have evaluable or measurable malignant disease at enrollmentXx_NEWLINE_xXConfirmed and measurable metastatic melanoma with at least one measurable lesion for evaluation of responseXx_NEWLINE_xXRadiologically measurable disease by immune-related Response Criteria (irRC).Xx_NEWLINE_xXEvaluable diseaseXx_NEWLINE_xXEvaluable or measurable radiographic evidence of colorectal cancerXx_NEWLINE_xXMeasurable or non-measurable disease will be allowedXx_NEWLINE_xXPatients with measurable disease defined as at least one of the followingXx_NEWLINE_xXHas at least one confirmed measurable metastatic lesionXx_NEWLINE_xXPatients must have measurable disease as defined in Section 10.1 (cutaneous lesions measuring at least 1 cm will be considered measurable). Baseline CT or MRI scans of measurable disease sites must be performed within 4 weeks of study entry.Xx_NEWLINE_xXThey must have recurrent melanoma with measurable or evaluable sites of disease, 1.0 cm or larger, in order to assess the response to treatment by the immune-related response criteriaXx_NEWLINE_xXMeasurable disease on computed tomography (CT) or evaluable disease with an elevated prostate specific antigen (PSA)Xx_NEWLINE_xXPresence of measurable or evaluable diseaseXx_NEWLINE_xXMeasurable tumorXx_NEWLINE_xXAt least one bidimensionally measurable lesionXx_NEWLINE_xXNon-measurable or measurable, metastatic diseaseXx_NEWLINE_xXRadiologically measurable diseaseXx_NEWLINE_xXMeasurable disease by International Working Group (IWG) response criteria for lymphomaXx_NEWLINE_xXPresence of measurable disease meeting the following criteria:Xx_NEWLINE_xXMeasurable disease by CT or MRIXx_NEWLINE_xXAt least one measurable lesion per revised IWG Response CriteriaXx_NEWLINE_xXPrior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiatedXx_NEWLINE_xXMeasurable disease assessed by one of the following ?21 days prior to registration:Xx_NEWLINE_xXMeasurable disease with elevated PSA or evaluable disease (PSA elevation will constitute evaluable disease)Xx_NEWLINE_xXAll patients must have no measurable disease. Measurable disease is defined as lesions that can be measured by physical examination or by means of imaging techniques. Imaging must be done within 6 weeks of study entry.Xx_NEWLINE_xXSubjects must have at least 1 measurable lesion.Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXPatients may have either non-measurable disease OR measurable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXPresence of at least one lesion of bi-dimensionally measurable disease on baselineXx_NEWLINE_xXEvaluable disease or disease measurableXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXAt least one radiologically-confirmed and measurable metastatic brain lesion ( ? 0.5 cm)Xx_NEWLINE_xXMeasurable disease will be required; biopsiable disease will be requiredXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatient must have relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease. Patients must have CNS 1 disease. Patient must have histologic verification of disease at original diagnosis. Patient must have measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entry.Xx_NEWLINE_xXSubjects who have locally recurrent or metastatic disease with at least one measurable lesionXx_NEWLINE_xXMeasurable disease is not required for study participationXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXBi-dimensionally measurable disease within the boneXx_NEWLINE_xXPatients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease; measurable disease must be assessed within 30 days prior to registration per response evaluation criteria in solid tumors (RECIST) version (v)1.1; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non- measurable disease must be assessed within 30 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment FormXx_NEWLINE_xXHave measurable or evaluable disease.Xx_NEWLINE_xXPatients may have measurable or non-measurable but evaluable disease.Xx_NEWLINE_xXAt least one measurable lesion that is > 1.5 cm in at least one dimensionXx_NEWLINE_xXOnly evidence of disease is non-measurable.Xx_NEWLINE_xXDisease status must be that of measurable and/or evaluable diseaseXx_NEWLINE_xXHave measurable disease based on modified severity-weighted assessment tool (mSWAT); tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXPatients may have measurable or nonmeasurable but evaluable disease; patients with surgically resected metastatic disease at high risk of relapse are also eligibleXx_NEWLINE_xXImaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease done within 21 days prior to randomization. Patients with either measurable disease OR non-measurable evaluable disease will be eligible.Xx_NEWLINE_xXFor patients in the Phase II portion of the study, must have measurable disease defined by at least 1 of the following 3 measurements:Xx_NEWLINE_xXPatients must have measurable disease, documented by clinical, radiographic, or histologic criteria, and have relapsed or become refractory to conventional therapyXx_NEWLINE_xXPatients who have not had resection of recurrent or progressive disease must have measurable disease.Xx_NEWLINE_xXSurgery, radiotherapy, or lesion ablative procedure to the only area of measurable/evaluable diseaseXx_NEWLINE_xXMeasurable disease by radiographic or physical examinationXx_NEWLINE_xXMeasurable tumor lesions according to RANO working Group Criteria. a. In the case that there is \non-measurable\ disease due to a radical surgical resection during screening, the subject still qualifies if Inclusion #3(b) is met.Xx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXMeasurable disease in the breast or axilla that measures at least 1 cm by either clinical or radiographic measurementXx_NEWLINE_xXPatient has at least one measurable and/or non-measurable lesion as per RANO criteriaXx_NEWLINE_xXMeasurable disease (only for the phase II portion)Xx_NEWLINE_xXRadiographically measurable disease (>= 1 focus of lymphoma measuring >= 1.5 cm)Xx_NEWLINE_xXEvaluable disease. In the absence of lymphadenopathy, splenomegaly with defects or measurable extra-medullary disease is acceptableXx_NEWLINE_xXMay be treated with localized radiation as long as measurable or evaluable disease remains at untreated sites.Xx_NEWLINE_xXMeasurable disease based on Cheson 2007 criteriaXx_NEWLINE_xXMeasurable disease, as defined by 1 or more of the following (assessed within 21 days prior to randomization):Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXMay have measurable disease, non-measurable disease, or both.Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors.Xx_NEWLINE_xXMeasurable or non-measurable disease that has progressed since last treatment.Xx_NEWLINE_xXMeasurable or evaluable disease (as defined in the study protocol)Xx_NEWLINE_xXAt least one measurable lesion according to international workshop lymphoma response criteria; there must be measurable lymphadenopathy to follow with serial exam and/or imagingXx_NEWLINE_xXMeasurable disease requiring systemic therapyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatient has at least one measurable nodal lesion (?2 cm) according to Cheson criteria (Cheson 2007). In case where the patient has no measurable nodal lesions ? 2 cm in the long axis at baseline, then the patient must have at least one measurable extra-nodal lesion.Xx_NEWLINE_xXAll patients must have bi-dimensionally measurable disease with lesions at least 1.5 cm in one dimension all measurable disease must be assessed within 28 days of registrationXx_NEWLINE_xXMeasurable disease or non-measurable but evaluable disease, according to the RECIST v1.1; Participants with peritoneal disease would generally be regarded as having evaluable disease and allowed to enter the trialXx_NEWLINE_xXMeasurable disease, as indicated by one or more of the following:Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable or evaluable disease by gadolinium MRI or contrast CT scan; note: patients who have had a gross total resection (GTR) are eligible on the basis of evaluable diseaseXx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXAt least 1 lesion with measurable disease at baselineXx_NEWLINE_xXPatients must have measurable disease in two dimensions and >= 2 cm is acceptable (or 1.5 cm if 0.5 slices are used, as in spiral computed tomography [CT] scans); lesions that are considered intrinsically non-measurable include the following:\r\n* Bone lesions\r\n* Leptomeningeal disease\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Inflammatory breast disease\r\n* Lymphangitis cutis/pulmonis\r\n* Abdominal masses that are not confirmed and followed by imaging techniques\r\n* Cystic lesions\r\n* Lesions that are situated in a previously irradiated areaXx_NEWLINE_xXMeasurable or non-measurable diseaseXx_NEWLINE_xXPatients must have evaluable or measurable tumor(s)Xx_NEWLINE_xXMeasurable disease per RECIST 1.1 criteria. Subjects with non-measurable, but evaluable disease are also eligible for Part 1 of the study.Xx_NEWLINE_xXPatients must have measurable disease (Phase I)Xx_NEWLINE_xXPatients must have measurable disease; must have at least one non-nodal lesionXx_NEWLINE_xXEvaluable or measurable diseaseXx_NEWLINE_xXMeasurable Disease must be present either on physical examination or imaging studies; non-measurable disease alone is not acceptable; any tumor mass > 1 cm is acceptable; lesions that are considered non-measurable include the following:\r\n* Bone lesions\r\n* Leptomeningeal disease\r\n* Ascites\r\n* Pleural/pericardial effusion\r\n* Inflammatory breast disease\r\n* Lymphangitis cutis/pulmonis\r\n* Bone marrow involvement (involvement by non-Hodgkin lymphoma should be noted)Xx_NEWLINE_xXMeasurable disease as specified in study protocolXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXHas measurable disease as specified in study protocolXx_NEWLINE_xXPresence of measurable disease meeting the following criteria:Xx_NEWLINE_xXMeasurable disease of at least 1.5 cmXx_NEWLINE_xXPHASE I: Patients may have measurable or evaluable disease onlyXx_NEWLINE_xXPHASE II: All patients will be required to have measurable diseaseXx_NEWLINE_xXEvaluable or measurable diseaseXx_NEWLINE_xXRadiologic eligibility (measurable disease) must be must be confirmed by the BICR prior to randomization.Xx_NEWLINE_xXMeasurable disease per RECIST guidelines (subjects with non-measurable, but evaluable disease are also eligible for the dose escalation portion of the study)Xx_NEWLINE_xXHas measurable or nonmeasurable diseaseXx_NEWLINE_xXHave the presence of measurable or nonmeasurable diseaseXx_NEWLINE_xXMeasurable disease defined as at least one of the following:Xx_NEWLINE_xXMeasurable disease defined as at least one of the following:Xx_NEWLINE_xXMeasurable disease defined as at least one of the following:Xx_NEWLINE_xXBidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single dimensionXx_NEWLINE_xXMeasurable disease at the time of study entryXx_NEWLINE_xXPatients must have measurable disease; patients may or may not have cancer-related symptomsXx_NEWLINE_xXMeasurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization):Xx_NEWLINE_xXMeasurable lesions are not required for admittance to the study - but are desirable.Xx_NEWLINE_xXPatients must have measurable diseaseXx_NEWLINE_xXAt least one measurable lesion or evaluable diseaseXx_NEWLINE_xXtumors must be measurableXx_NEWLINE_xXBidimensionally measurable disease (field not previously radiated)Xx_NEWLINE_xXPatients must have evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXMeasurable evidence of active disease within 1 year before study enrollmentXx_NEWLINE_xXPresence of measurable or non-measurable disease.Xx_NEWLINE_xXPatients must meet one of the following two requirements:\r\n* Have achieved minimal response (MR) or stable disease (SD) in current treatment regimen after receiving a minimum of two cycles\r\n* Have a partial response but show a decrease less than 25% or an increase less than 25% in measurable disease over a two month period\r\n** NOTE: Patients may be refractory to primary therapy or relapsed and have measurable or assessable disease; (refractory disease is defined as anything less than partial response [PR] or progression within 60 days of completing therapy)Xx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXPatients must have bi-dimensional measurable diseaseXx_NEWLINE_xXHistologically confirmed diagnosis, measurable disease and evidence of disease progression of MM.Xx_NEWLINE_xXSymptomatic MM, based on IMWG guidelines. Patients must have measurable disease.Xx_NEWLINE_xXEvidence of measurable or evaluable diseaseXx_NEWLINE_xXMust have bi-dimensionally measurable diseaseXx_NEWLINE_xXHas measurable disease (or evaluable if not in MTD expansion cohort) via computed tomography (CT) or magnetic resonance imaging (MRI) scans with or without non-measurable tumors (a lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of that lesion prior to enrollment)Xx_NEWLINE_xXCOHORT A SPECIFIC INCLUSION: Measurable disease on imaging (1 cm) or measurable non-enhancing tumorXx_NEWLINE_xXMeasurable disease per IWG 2007 criteria.Xx_NEWLINE_xXHave measurable disease based on modified severity-weighted assessment tool (mSWAT); tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXRadiographically or clinically measurable disease with at least 1 target lesion per International Working Group (IWG) criteria for malignant lymphoma.Xx_NEWLINE_xXRadiologically measurable disease meeting the following criteria:Xx_NEWLINE_xXFor Parts A and B, participants must have evaluable or measurable diseaseXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Palpable lesions that are not measurable by radiographic or photographic evaluations may not be utilized as the only measurable lesion. Any measurable lesion biopsied at Screening cannot be followed as a target/index lesion unless agreed upon by GlaxoSmithKline (GSK).Xx_NEWLINE_xXDisease may be measurable or non-measurableXx_NEWLINE_xXPresence of evaluable diseaseXx_NEWLINE_xXMeasurable disease with obstruction into the airwayXx_NEWLINE_xXGENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice\r\n* Note: The following do not qualify as measurable disease:\r\n** Malignant fluid collections (e.g., ascites, pleural effusions)\r\n** Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\r\n** Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\r\n** Elevated tumor markers in plasma or CSF \r\n** Previously radiated lesions that have not demonstrated clear progression post radiation \r\n** Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease on preoperative imagingXx_NEWLINE_xXPatients who have measurable disease after diagnostic biopsyXx_NEWLINE_xXMeasurable disease – minimum lesion size of 8 x 3 mm before initial biopsyXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMust have measurable or evaluable diseaseXx_NEWLINE_xXAt least one site of measurable diseaseXx_NEWLINE_xXParticipants must have measurable or evaluable diseaseXx_NEWLINE_xXMeasurable diseaseXx_NEWLINE_xXMeasurable disease, including at least one of the following:Xx_NEWLINE_xXMeasurable disease as per IMWG response criteriaXx_NEWLINE_xXExtramedullary disease in the absence of any measurable medullary involvementXx_NEWLINE_xXSubjects must have measurable diseaseXx_NEWLINE_xXMeasurable hepatic disease and/or presence of vascular tumor thrombosisXx_NEWLINE_xXDisease that is measurable; this is defined as lesions measuring at least 10 mm on radiologic imagingXx_NEWLINE_xXParticipants in the Kinetic Studies Arm cannot have non-measurable disease (< 1 cm) by CTXx_NEWLINE_xXAll patients must have measurable or evaluable diseaseXx_NEWLINE_xXSubjects must have had radiographically evaluable or measurable disease with standard magnetic resonance (MR) imagingXx_NEWLINE_xXPatient must have measurable residual disease, defined as tumor that is measurable in two perpendicular diameters on MRI; diffuse leptomeningeal disease is not considered measurableXx_NEWLINE_xXMeasurable disease.Xx_NEWLINE_xXHave measurable disease based on irRECISTXx_NEWLINE_xXMeasurable disease (assessed within 28 days prior to day 1)Xx_NEWLINE_xXPatients who only have non-measurable diseaseXx_NEWLINE_xXRadiographic evidence of unidimensionally measurable disease; lesions will be considered measurable or non-measurable as per definitions provided in RECIST version 1.1Xx_NEWLINE_xXMeasurable disease on CT scanXx_NEWLINE_xXMeasurable disease (at least one lesion on radiographic or exam assessment measuring >= 2 cm in longest axis)Xx_NEWLINE_xXMeasurable Disease:Xx_NEWLINE_xXPart 2, Expansion: Participants must have measurable disease meeting the following criteria: i. Subjects with HCC: At least 1 measurable target lesion according to mRECISTXx_NEWLINE_xXMeasurable or non-measurable disease will be allowedXx_NEWLINE_xXFor Participants with MM, measurable disease defined as one of the following:Xx_NEWLINE_xXMeasurable or evaluable diseaseXx_NEWLINE_xXThe participant has measurable or non-measurable disease.Xx_NEWLINE_xXAt least one measurable lesion per revised IWG Response CriteriaXx_NEWLINE_xXAt least one lesion with measurable disease at baselineXx_NEWLINE_xXMeasurable disease as per modified RECIST 1.1 • A lesion in an area that was previously treated with local therapy (e.g. radiation, surgery, or cryotherapy) can be considered measurable disease as long as there is objective evidence of progression of the lesion prior to randomizationXx_NEWLINE_xXPresence of measurable diseaseXx_NEWLINE_xXMeasurable disease meeting the following criteria and confirmed by central radiographic review:Xx_NEWLINE_xXDocumentation of target and non-target lesion(s) status per RECIST1.1 post induction chemotherapy for patients with evaluable disease\r\n* Note: Evaluable disease is not required for study entry (patients with complete response [CR] or response sufficient to preclude measurable lesions are not excluded; such patients will be evaluated for PFS and OS, but not for response)Xx_NEWLINE_xXConfirmed measurable diseaseXx_NEWLINE_xXAt least one measurable lesionXx_NEWLINE_xX